Rivaroxaban: an oral factor xa inhibitor.
CONCLUSIONS: Based on the findings of the studies reported in this review, rivaroxaban is an effective option for the prevention of VTE after orthopedic surgery, stroke prevention for nonvalvular AF, and treatment of VTE. At this time, rivaroxaban cannot be recommended for secondary risk reduction after ACS because of the increased bleeding risk.
PMID: 23328267 [PubMed - in process]
Source: Clinical Therapeutics - Category: Drugs & Pharmacology Authors: Thomas TF, Ganetsky V, Spinler SA Tags: Clin Ther Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Clinical Trials | Coronary Artery Bypass Graft | Drugs & Pharmacology | Heart | Hemorrhagic Stroke | Laboratory Medicine | Lovenox | Orthopaedics | Pulmonary Thromboembolism | Statistics | Stroke | Study | Thrombosis | Vitamins